Pharmacological properties of MM-706, a new prostacyclin derivative.

@article{Ragazzi1995PharmacologicalPO,
  title={Pharmacological properties of MM-706, a new prostacyclin derivative.},
  author={Eugenio Ragazzi and Alessandro Chinellato and U. Lille and Margus Lopp and Maria Gabriella Doni and Giuliana Fassina},
  journal={General pharmacology},
  year={1995},
  volume={26 4},
  pages={
          703-9
        }
}
View on PubMed
doi.org
4 Citations
Background Citations
1
Results Citations
1

4 Citations

Inhibition of platelet activation by MM-706, a stable carbacyclin analog, in the conscious rat.
Neuronal prostacyclin receptors.
  • H. Wise
  • Biology, Medicine
    Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques
  • 1997
TLDR
It is hoped that this review of recent developments in the study of neuronal prostacyclin receptors will set the scene for what is a rapidly developing and exciting area of research.
PROSTANOID ACTION ON THE HUMAN PULMONARY VASCULAR SYSTEM
TLDR
Four types of prostanoid receptor are present on pulmonary arterial vessels of man and mediate constriction, the agonist potency ranking being SC 46275 > sulprostone > misoprostol≥PGE2; this action needs to be borne in mind when PGE analogues are used therapeutically.
Thromboxane A2 and Other Eicosanoids
TLDR
This chapter will provide a brief discussion of alterations in platelet TXA2 receptors in disease states and focus on discoveries made since Arita et al. (1989).

References

SHOWING 1-10 OF 27 REFERENCES
Comparison of the vasodepressor action of ZK 36 374, a stable prostacyclin derivative, PGI2 and PGE1 with their effect on platelet aggregation and bleeding time in rats.
Synthesis and anti-aggregative activity of novel ω-achiral carba-analogues of prostacyclin
Effect of cyclic AMP on cytoplasmic free calcium in human platelets stimulated by thrombin: direct measurement with quin2.
The putative prostacyclin receptor antagonist (FCE-22176) is a full agonist on human platelets and NCB-20 cells.
Modulation of human platelet adenylate cyclase by prostacyclin (PGX).
The cytoplasmic concentration of free calcium in platelets is controlled by stimulators of cyclic AMP production (PGD2, PGE1, forskolin).
Pharmacokinetics and Platelet Antiaggregating Effects of Beraprost, an Oral Stable Prostacyclin Analogue, in Healthy Volunteers
TLDR
Data indicate that orally active prostacyclin BPS (40 or 60 μg) exerts its maximal antiaggregating effects between 0.5 and 1 h, and that some subjects complained of moderate postdrug absorption headaches and flushes.
Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.
TLDR
Iloprost provides a pharmacotherapeutic option for patients with severe peripheral vascular disease, a condition for which few alternative drug therapies exist and its potent but short-lived effects make it well-suited to certain therapeutic niches such as the management of intraoperative platelet activation.
Forskolin and prostacyclin inhibit fluoride induced platelet activation and protein kinase C dependent responses.
Interaction of FCE 22176, a stable prostacyclin analogue, with different prostaglandins in guinea-pig trachea and atria.
...
...